CEACAM5 and medullary thyroid gland carcinoma: Two clinical trials are on-going in France, aiming at optimizing and assessing pretargeted immuno-PET, using anti-CEA TF2 and 68Ga-IMP288 in patients with relapsed MTC and HER2-negative breast cancer.